Arkstone Revolutionizes Maternal Care with NeoSure Integration into OneChoice Reports

Arkstone's NeoSure™: A New Era in Maternal Care

Arkstone has recently unveiled its latest innovation, NeoSure™, which significantly enhances the OneChoice platform, aimed at improving maternal care by incorporating crucial breastfeeding safety data. This latest advancement presents an opportunity to provide healthcare professionals with well-rounded guidance concerning antimicrobial treatments during pregnancy and breastfeeding.

Historically, managing antimicrobial treatment during pregnancy and nursing has posed unique challenges. Certain medications not only have potential risks for fetal development but may also affect infant health if transmitted through breast milk. With NeoSure™, healthcare providers can reference a more exhaustive set of recommendations tailored specifically for pregnant and breastfeeding mothers.

Dr. Ari Frenkel, Arkstone's Chief Science Officer, stated, "With NeoSure™, we're expanding our commitment to maternal and infant safety. OneChoice has already assisted clinicians by offering guidance on safe prescribing during pregnancy. By incorporating breastfeeding insights, we are delivering a comprehensive solution where uncertainties once existed."

The NeoSure™ innovation introduces several pivotal updates to the OneChoice reports:

Expanded Maternal Care Framework

NeoSure™ boosts OneChoice's existing capability by not only accounting for pregnancy status but also integrating breastfeeding safety guidelines. This provides a full-circle maternal care solution, enhancing the platform's usability for healthcare providers.

Real-Time Input from Labs and Clinicians

The platform allows labs to submit essential data like pregnancy and breastfeeding status during patient data entry, enabling clinicians access to updated information that can influence prescribing decisions instantly.

Minimizing Infant Risk

NeoSure™ aims to assist healthcare professionals in modifying medication selections and timing breastfeeding schedules suitably to lessen unnecessary exposure to infants, while still ensuring effective treatment for mothers.

According to Dave Gross, Chief Technology Officer of Arkstone, "NeoSure™ amplifies the OneChoice's capabilities through our Antimicrobial Intelligence framework, ensuring that clinicians receive the most precise, evidence-based recommendations available. By incorporating breastfeeding safety data, we empower providers to prescribe confidently, safeguarding both mother and child."

NeoSure™ is a testament to Arkstone's dedication to fostering advanced antimicrobial stewardship through precision medicine. This expansion of the OneChoice platform illustrates its industry-leading position, ensuring that prescriptions are considerate of both pregnancy and breastfeeding safety, which ultimately aids healthcare providers in making the best-informed choices for their patients.

About Arkstone

Arkstone is a pioneer in infectious disease diagnosis and antimicrobial stewardship. By leveraging its AI-enhanced solutions, it offers evidence-based recommendations to combat misuse and resistance, facilitating smarter and safer prescribing practices across the globe.

For additional insights, visit www.arkstone.ai or contact their media relations team.